Immunosenescence is emerging as a driver of organism aging. Oral administration of NMN (Product CHANTIAGINGTM VitalNAD) as NAD+ supplementation improves subjects’ performance in aging assessment. To explore whether NAD+ alleviates aging through improving immune fitness, 11 healthy volunteers (Clinical trial: NCT05984550) were scheduled to take 600 mg NMN (po, qd) for 30 days, and biomarkers broadly used for immune fitness were examined in PBMC at day7 and day30. Successful NMN intake by the PBMCs was demonstrated by the elevation of NAD+ level, especially in participants with lower baseline NAD+ level, who benefit more in terms of the biomarkers. Specifically, biomarkers of exhaustion and declined function of immune cells, such as PD1, LAG3, CD57 and KLRG1, were down-regulated at day7 and day30; Tn/Tcm and mitochondria membrane potential were up-regulated. These alterations indicate improvement of immune fitness by NAD+.
To further validate the impact of VitalNAD on immunosenescence, we constructed a mathematic model to calculate the ‘immuno-age’. Baseline ‘immuno-age’ were highly correlated to the biological ages (r = 0.72); ‘immuno-age’ at day7 was 3% to 19% (1 to 7-years) younger than the biological age. ‘Immuno-age’ of 80% participants were still lower at day30, comparable to day7. However, only 45% remained younger 45 days after the last administration of NMN. Seemingly, NMN supplementation is a promising intervention for aging, and persistent administration helps maintain the anti-aging effect. The novel ‘immuno-age’ prediction using the above-mentioned biomarkers may be further applied in clinical evaluation of immunosenescence.

Authors:
Qijun Qian, Shanghai Cell Therapy Group Corporation, China
Yan Sun, Shanghai Cell Therapy Group Corporation, China
Lijie Rong, Shanghai Cell Therapy Group Corporation, China
Zhicai Lin, Shanghai Cell Therapy Group Corporation, China
Xinhao Wang, Shanghai Cell Therapy Group Corporation, China
Hongwei Yang, Shanghai Cell Therapy Group Corporation, China

About the Presenter(s)
Dr. Lijie Rong is currently Director of Translational Medicine Center at Shanghai Cell Therapy Group, Shanghai, China. Dr. Rong’s research interests focus on cell therapies against aging and cancer.

See this presentation on the full schedule – Tuesday Schedule

Bookmark